低级别分支胰管型IPMN剜除术的长期随访结果
影像学随访显示10例(18%)出现IPMN复发,4例(6%)再手术,无IPMN相关死亡及新发胰岛素依赖型糖尿病,生活质量评分良好。结论认为剜除术是低级别分支胰管型IPMN的保器官治疗选择,局部复发风险低且功能预后优异,但术后需终身随访。
要点
- 剜除术治疗低级别分支胰管型IPMN的局部复发风险低(5%),但总体复发率18%。
- 术后中位87个月随访中无IPMN相关死亡,无新发胰岛素依赖型糖尿病。
- 术后需终身随访,因存在复发及潜在恶变风险。
核心结论
- 剜除术是低级别分支胰管型IPMN的保器官手术选择,局部复发风险低且长期功能预后优异。
- 术后仍需终身随访,因存在复发和潜在恶变风险。
研究设计与样本
- 66例(89%)获得长期随访数据,中位随访87个月。
- 生活质量采用EORTC QLQ-C30和QLQ-PAN26问卷评估。
主要发现
- 影像学随访56例中10例(18%)出现IPMN复发,其中局部复发3例(5%),胰 remnant远处新发7例(13%)。
- 4例(6%)接受再手术,其中2例为IPMN相关癌(1例位于剜除部位)。
- 随访期间无IPMN相关死亡,无新发胰岛素依赖型糖尿病。
- QLQ-C30总体健康状况66.0%,总体功能和症状评分分别为81.0%和22.8%;QLQ-PAN26总体症状评分26.5%。
临床怎么用
- 对于低级别分支胰管型IPMN,剜除术可作为保留胰腺实质的手术选项。
- 术后应按部分胰腺切除术后的IPMN随访原则进行终身影像学监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pancreatic enucleation allows resection of branch-duct intraductal papillary mucinous neoplasms with full parenchyma preservation. The aim of this study was to assess intraductal papillary mucinous neoplasms recurrence and functional outcomes during long-term follow-up after enucleation. METHODS: Patient characteristics, as well as radiologic and clinicopathologic follow-up data of patients who underwent enucleation for branch-duct intraductal papillary mucinous neoplasms between 2004 and 2014, were analyzed. Quality of life was assessed using the EORTC QLQ-C30 and QLQ-PAN26 questionnaires. RESULTS: Seventy-four patients underwent enucleation for low-grade branch-duct intraductal papillary mucinous neoplasms in 71 and high-grade branch-duct intraductal papillary mucinous neoplasms in 3 patients. Long-term follow-up data were available for 66 patients (89%; median follow-up: 87 months). Radiologic imaging (n = 56) showed intraductal papillary mucinous neoplasm recurrence in 10 patients (18%) including local recurrence at the site of enucleation in 3 patients (5%) and new onset intraductal papillary mucinous neoplasms manifestation in 7 patients (13%) at a distant site in the pancreatic remnant. Four patients (6%) underwent reoperation. Two of these patients had intraductal papillary mucinous neoplasm-associated carcinoma, one of them at the enucleation site. During the follow-up period, no intraductal papillary mucinous neoplasm-related deaths occurred and no new onsets of insulin-dependent diabetes mellitus were observed. QLQ-C30 revealed a global health status of 66.0% and overall functioning and symptom scores of 81.0% and 22.8%, respectively. Additionally, QLQ-PAN26 showed an overall symptom score of 26.5%. CONCLUSION: Enucleation is an organ-preserving surgical treatment option for low-grade branch-duct intraductal papillary mucinous neoplasms with low local recurrence risk and excellent functional long-term outcome. However, postoperative life-long follow-up must be performed as for any type of partial pancreatectomy for intraductal papillary mucinous neoplasms due to the risk of recurrence and potential malignancy.
引用
- Kaiser J, Alhalabi KT, Hinz U, et al. Enucleation for low-grade branch duct intraductal papillary mucinous neoplasms: Long-term follow-up. Surgery. 2022. PMID: 35680446. doi:10.1016/j.surg.2022.04.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。